GeniPhys has filed a notice of an exempt offering of securities to raise $5,550,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, GeniPhys is raising up to $5,550,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About GeniPhys
GeniPhys is developing and commercializing its patented Collymer technology -a first-of-a-kind polymerizable (scaffold-forming) collagen that supports custom design and fabrication of collagen materials for accelerated and improved tissue restoration and regeneration.? Pre-clinical studies demonstrate that Collymer materials exhibit an uncommon mode of action, providing a long-lasting and physically-stable scaffold that supports site-appropriate tissue integration and new tissue formation, avoiding inflammation, fibrosis, and scarring. Potential material applications extend from regenerative tissue replacements (including soft tissue, cardiovascular, musculoskeletal, and orthopedic) to delivery of pharmaceutical and cell-based therapies and to sensor/device coatings.
To learn more about GeniPhys, visit https://www.geniphys.com/
GeniPhys Linkedin Page: https://www.linkedin.com/company/geniphys/
Contact:
Andrew Eibling, Chief Executive Officer
317-797-8335
https://www.linkedin.com/in/aeibling/
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.